Medical Oncologist
Mutation testing and targeted therapy
KIT and PDGFRA Mutations in GIST — and the Drugs That Target Them
Most gastrointestinal stromal tumours carry a mutation in the KIT or PDGFRA gene. These mutations are the direct target for a class of drugs called tyrosine kinase inhibitors — and knowing exactly which mutation you have determines which drug your oncologist will recommend.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Mutation type determines your drug — The specific location of your KIT or PDGFRA mutation guides which tyrosine kinase inhibitor is most likely to help and at what dose.
- Treatment is usually a daily tablet — Most tyrosine kinase inhibitors used in GIST are taken orally at home. Hospital infusions are not required for these drugs.
- Testing uses tissue you have already given — Mutation testing is done on your biopsy or surgical sample. A new procedure is rarely needed at the start of treatment.
- A sequence of drugs is available — If one drug stops working, NCCN and ESMO guidelines support switching to a next-line option. You are not limited to a single treatment.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
KIT and PDGFRA are genes that, when mutated, drive the growth of most gastrointestinal stromal tumours. Targeted drugs called tyrosine kinase inhibitors — including imatinib, sunitinib, and avapritinib — work by blocking the mutated protein. Which drug is used first, and what follows, depends on your specific mutation.
What do KIT and PDGFRA mutations mean for your treatment?
KIT and PDGFRA are genes that make receptor proteins on the surface of cells. When either gene is mutated, the protein sends a constant growth signal — and that is what drives a GIST to form and grow.
Tyrosine kinase inhibitors are targeted drugs, taken as tablets, that switch off that signal. Most people with GIST start on imatinib, which blocks the mutated KIT or PDGFRA protein directly.
The specific location of your mutation — which gene is affected and which part of that gene — determines which drug is most likely to help and, for some mutations, what dose gives the best response. This is why mutation testing is done before treatment begins, not as an afterthought.
How does mutation testing decide which drug you get?
Tumour tissue is tested in a laboratory
A sample from your biopsy or surgery is analysed to identify whether a KIT or PDGFRA mutation is present and exactly where in the gene it sits. Results usually take one to two weeks.
Your oncologist matches the mutation to the right drug
KIT exon 11 mutations respond well to standard-dose imatinib. KIT exon 9 mutations may need a higher dose, as noted in NCCN and ESMO guidance. The PDGFRA D842V mutation responds specifically to avapritinib rather than imatinib.
You start first-line treatment
For most people this is imatinib, taken as a daily tablet at home. You do not need hospital infusions for the oral drugs used in GIST.
Scans check whether treatment is working
Response is assessed by CT or PET-CT scan at set intervals after starting treatment. Your oncologist uses those results to decide whether to continue or switch.
A next-line drug is used if the tumour progresses
NCCN and ESMO recommend sunitinib after imatinib progression, regorafenib after sunitinib, and ripretinib as a further option. Your oncologist sequences these based on your mutation profile and overall health.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What should you confirm before starting treatment?
- Ask for your mutation result in writing — which gene (KIT or PDGFRA), which exon, and which specific change was found.
- Ask whether your mutation affects the starting dose of imatinib.
- Ask how often you will be reviewed and what scans will check response.
- Ask what happens if imatinib stops working and what the next option would be.
- Ask whether surgery plays a role alongside your drug treatment.
- Tell your oncologist about any Ayurvedic, herbal, or over-the-counter preparations you are taking — some interact with tyrosine kinase inhibitors.
What if your GIST has no KIT or PDGFRA mutation?
A smaller proportion of GISTs carry neither mutation. These are called wild-type GISTs. Being wild-type does not mean there is no driver — it means the driver is something other than KIT or PDGFRA.
Wild-type GISTs may carry changes in the SDH gene complex, the NF1 gene, or other pathways. They behave differently from KIT-driven GIST, and NCCN guidance recognises them as a distinct group requiring individualised planning.
If you have wild-type GIST, your oncologist may recommend specialist review or discussion of a clinical trial. The absence of a KIT or PDGFRA mutation is not a reason to stop exploring options.
Which drugs are used for KIT and PDGFRA mutations in GIST?
- Imatinib
- A tyrosine kinase inhibitor taken as a daily tablet. First-line treatment for most KIT-mutated and some PDGFRA-mutated GISTs. Also used for three years after surgery in people with high-risk resected disease, as recommended by NCCN and ESMO.
- Sunitinib
- Second-line tyrosine kinase inhibitor used when imatinib stops controlling the tumour. Targets a broader range of proteins than imatinib and is taken on a specified dosing schedule.
- Regorafenib
- Third-line option used after both imatinib and sunitinib have been tried. Listed in NCCN and ESMO guidance as a standard recommendation at this stage.
- Avapritinib
- A targeted inhibitor approved specifically for the PDGFRA D842V mutation, which does not respond well to imatinib. NCCN guidance lists avapritinib as the recommended first-line drug for this mutation subgroup.
- Ripretinib
- A later-line option for GIST that has progressed through earlier tyrosine kinase inhibitors. Designed to work across a range of KIT and PDGFRA mutation types and included in NCCN guidance for use at the fourth line.
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
What is the PDGFRA D842V mutation and why does it need a different drug?
PDGFRA D842V is a specific change in the PDGFRA gene that makes the tumour resistant to imatinib, the drug used for most other GISTs. When imatinib was the only available option, people with this mutation did not benefit from standard first-line treatment. Avapritinib was developed specifically to block this mutation and is now the recommended first-line drug for PDGFRA D842V GIST under NCCN guidance. If you have this mutation, ask your oncologist explicitly about avapritinib.
How long will I need to take imatinib?
For metastatic or unresectable GIST, imatinib is continued for as long as it controls the disease — often for many years. Stopping it early is associated with rapid progression even in people who responded well. For people who had surgery for localised high-risk GIST and are taking imatinib to reduce the chance of recurrence, NCCN and ESMO recommend a three-year course. Your oncologist will tell you which situation applies to you.
Will I need a new biopsy if my GIST comes back?
Possibly, and it is worth asking about. Tumours can acquire new mutations when they progress through treatment, and the mutation driving a recurrence may differ from the one identified originally. Knowing the current mutation profile helps your oncologist choose the most appropriate next drug. If a repeat biopsy is not technically possible, your oncologist may use the original results alongside clinical judgement about which drug to try next.
Is GIST hereditary?
Most GISTs are not hereditary. The KIT and PDGFRA mutations that drive them arise during a person's lifetime in a single cell and are not passed on to children. A small number of GISTs occur as part of inherited syndromes, including familial GIST syndrome, Carney-Stratakis syndrome, and neurofibromatosis type 1. If you were diagnosed at a young age, have a family history of GIST, or have other features that concern your oncologist, ask whether a referral to a genetics specialist is appropriate.
How will I know if imatinib is working?
The main way is through imaging. CT or PET-CT scans done at intervals after starting treatment show whether the tumour has responded. A response on PET-CT can sometimes be visible within weeks of starting imatinib, even before the tumour visibly shrinks on CT. Your oncologist will also track symptoms and blood tests between scans. If you develop new pain, notice a swelling, or feel any change, tell your team rather than waiting for the next scheduled scan.
Can I get these GIST drugs at CION?
The tyrosine kinase inhibitors used in GIST — imatinib, sunitinib, regorafenib, avapritinib, and ripretinib — are all taken as tablets at home, so your visits to CION are for review, blood tests, and scan coordination rather than drug administration. PET-CT scans used to assess response are coordinated with partner imaging centres. If avapritinib is relevant to your mutation, ask at your CION centre whether it is accessible through your current treatment plan.